This case highlights the potential role of IL-31 in cholestatic pruritus and suggests that IL-31 blockade with nemolizumab may be an effective therapeutic option for refractory pruritus in pediatric patients with BA, warranting further investigation into its broader clinical applications beyond AD. This evidence concerns the gene IL31 and Alzheimer disease.